COSCIENS Biopharma Inc. engages in the development and commercialization of diverse pharmaceutical and diagnostic products. The company is headquartered in Toronto, Ontario. The firm is developing and commercializing a diversified portfolio of products for the cosmeceutical, nutraceutical and pharmaceutical markets. The Company’s patented technologies include the Pressurized Gas eXpanded (PGX) technology, which is a technology that generates high-value yields of active ingredients from natural-based resources for use in novel cosmeceutical, nutraceutical and pharmaceutical products. The firm's two products, oat beta glucan and avenanthramides, are found in household-name cosmetic and personal care brands. These products are manufactured from the Company’s proprietary oat extraction manufacturing technology and are known for their well-documented health benefits. Its lead product, macimorelin (Macrilen; Ghryvelin), is the oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD).
Leveraging in-depth analyst evaluations, we have synthesized key insights from expert assessments to present a positive outlook for CSCI. Analysts highlight solid fundamentals and favorable market sentiment, suggesting upside potential in the near term. Based on this thorough expert analysis, we maintain an optimistic view of this stock. Our conclusion: CSCI is a Buy candidate.
CSCI stock price ended at $2.7 on 金曜日, after rising 3.45%
On the latest trading day Oct 03, 2025, the stock price of CSCI rose by 3.45%, climbing from $2.62 to $2.70. During the session, the stock saw a volatility of 3.05%, with prices oscillating between a daily low of $2.62 and a high of $2.70. Notably, trading volume dropped by 25 shares on the last day despite the price increase, which may signal a potential uptick in risk in the near term. A total of 882 shares were traded, equating to a market value of approximately $8.7M.